Application of specific cell permeable cathepsin G inhibitors resulted in reduced antigen processing in primary dendritic cells

Molecular Immunology

Volumn 46, Issue 15, 2009, Pages 2994-2999

  Reich, Michael ^a   Lesner, Adam ^b   Łegowska, Anna ^b   Sieńczyk, Marcin ^c   Oleksyszyn, Jozef ^c   Boehm, Bernhard O ^a   Burster, Timo ^a  

^a Division of Endocrinology and Diabetes   (Germany)

^b UNIVERSITY OF GDA SK   (Poland)

^c WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Antigen presentation processing; Cathepsin G; Specific CatG inhibitors

Indexed keywords

CATHEPSIN G; CATHEPSIN G INHIBITOR; GAMMA INTERFERON; INTERLEUKIN 17; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; COVALENT BOND; CYTOKINE RELEASE; DENDRITIC CELL; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN CONTENT; T LYMPHOCYTE ACTIVATION;

ANTIGEN PRESENTATION; B-LYMPHOCYTES; CATHEPSINS; CD4-POSITIVE T-LYMPHOCYTES; CELL MEMBRANE PERMEABILITY; DENDRITIC CELLS; HEMAGGLUTININS; HUMANS; PEPTIDE FRAGMENTS; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; TETANUS TOXIN;

EID: 68749094973     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2009.06.017     Document Type: Article

References (24)

1. Bennett K., Levine T., Ellis J.S., Peanasky R.J., Samloff I.M., Kay J., and Chain B.M. Antigen processing for presentation by class II major histocompatibility complex requires cleavage by cathepsin E. Eur J Immunol 22 (1992) 1519-1524
2. Bryant P., and Ploegh H. Class II MHC peptide loading by the professionals. Curr Opin Immunol 16 (2004) 96-102
3. Burster T., Beck A., Tolosa E., Marin-Esteban V., Rotzschke O., Falk K., Lautwein A., Reich M., Brandenburg J., Schwarz G., Wiendl H., Melms A., Lehmann R., Stevanovic S., Kalbacher H., and Driessen C. Cathepsin G, and not the asparagine-specific endoprotease, controls the processing of myelin basic protein in lysosomes from human B lymphocytes. J Immunol 172 (2004) 5495-5503
4. Burster T., Beck A., Tolosa E., Schnorrer P., Weissert R., Reich M., Kraus M., Kalbacher H., Haring H.U., Weber E., Overkleeft H., and Driessen C. Differential processing of autoantigens in lysosomes from human monocyte-derived and peripheral blood dendritic cells. J Immunol 175 (2005) 5940-5949
5. Burster T., Reich M., Zaidi N., Voelter W., Boehm B.O., and Kalbacher H. Cathepsin E regulates the presentation of tetanus toxin C-fragment in PMA activated primary human B cells. Biochem Biophys Res Commun 377 (2008) 1299-1303
6. Chain B.M., Free P., Medd P., Swetman C., Tabor A.B., and Terrazzini N. The expression and function of cathepsin E in dendritic cells. J Immunol 174 (2005) 1791-1800
7. Greenbaum D., Medzihradszky K.F., Burlingame A., and Bogyo M. Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. Chem Biol 7 (2000) 569-581
8. Hewitt E.W., Treumann A., Morrice N., Tatnell P.J., Kay J., and Watts C. Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase. J Biol Chem 21 (1997) 8090-8098
9. James G.T. Inactivation of the protease inhibitor phenylmethylsulfonyl fluoride in buffers. Anal Biochem 86 (1978) 574-579
10. Łe{ogonek}gowska A., Debowski D., Lesner A., Wysocka M., and Rolka K. The introduction of non-natural amino acid residues into the substrate specificity P1 position of trypsin inhibitor SFTI-1 yields potent chymotrypsin and cathepsin G inhibitors. Bioorg Med Chem 17 (2009) 3302-3307
11. Łe{ogonek}gowska, A., De{ogonek}bowski, D., Lesner, A., Wysocka, M., Rolka, K., 2009b. Selection of peptomeric inhibitors of bovine α-chymotrypsin and cathepsin G based on trypsin inhibitor SFTI-1 using a combinatorial chemistry approach. Mol Divers, doi:10.1007/s11030-009-9142-z.
12. Nishioku T., Hashimoto K., Yamashita K., Liou S.Y., Kagamiishi Y., Maegawa H., Katsube N., Peters C., von Figura K., Saftig P., Katunuma N., Yamamoto K., and Nakanishi H. Involvement of cathepsin E in exogenous antigen processing in primary cultured murine microglia. J Biol Chem 277 (2002) 4816-4822
13. Oleksyszyn J., and Powers J.C. Irreversible inhibition of serine proteases by peptide derivatives of (alpha-aminoalkyl)phosphonate diphenyl esters. Biochemistry 30 (1991) 485-493
14. Reich M., Wieczerzak E., Jankowska E., Palesch D., Boehm B., and Burster T. Specific cathepsin B inhibitor is cell permeable and activates presentation of TTC in primary human dendritic cells. Immunol Lett 123 (2009) 155-159
15. Riese R.J., Wolf P.R., Bromme D., Natkin L.R., Villadangos J.A., Ploegh H.L., and Chapman H.A. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity 4 (1996) 357-366
16. Rudensky, A., Beers, C., 2006. Lysosomal cysteine proteases and antigen presentation. Ernst Schering Res Found Workshop, pp. 81-95.
17. Sienczyk M., Lesner A., Wysocka M., Łe{ogonek}gowska A., Pietrusewicz E., Rolka K., and Oleksyszyn J. New potent cathepsin G phosphonate inhibitors. Bioorg Med Chem 16 (2008) 8863-8867
18. Stoeckle C., Sommandas V., Adamopoulou E., Belisle K., Schiekofer S., Melms A., Weber E., Driessen C., Boehm B.O., Tolosa E., and Burster T. Cathepsin G is differentially expressed in primary human antigen-presenting cells. Cell Immunol 255 (2009) 41-45
19. Villadangos J.A., Riese R.J., Peters C., Chapman H.A., and Ploegh H.L. Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism. J Exp Med 186 (1997) 549-560
20. Watts C., Matthews S.P., Mazzeo D., Manoury B., and Moss C.X. Asparaginyl endopeptidase: case history of a class II MHC compartment protease. Immunol Rev 207 (2005) 218-228
21. Watts C., Moss C.X., Mazzeo D., West M.A., Matthews S.P., Li D.N., and Manoury B. Creation versus destruction of T cell epitopes in the class II MHC pathway. Ann N Y Acad Sci 987 (2003) 9-14
22. Yasuda Y., Li Z., Greenbaum D., Bogyo M., Weber E., and Bromme D. Cathepsin V, a novel and potent elastolytic activity expressed in activated macrophages. J Biol Chem 279 (2004) 36761-36770
23. Zaidi N., Burster T., Sommandas V., Herrmann T., Boehm B.O., Driessen C., Voelter W., and Kalbacher H. A novel cell penetrating aspartic protease inhibitor blocks processing and presentation of tetanus toxoid more efficiently than pepstatin A. Biochem Biophys Res Commun 364 (2007) 243-249
24. Zavasnik-Bergant T., and Turk B. Cysteine cathepsins in the immune response. Tissue Antigens 67 (2006) 349-355